Medical AISTEP 1: semaglutide for obesity - the pivotal trial.
In adults with obesity who did not have diabetes, once-weekly semaglutide 2.4 mg produced about 14.9% mean weight loss over 68 weeks, versus about 2.4% on placebo. Here is what the trial measured, who it enrolled, and why it underpinned the Wegovy approval.
STEP 1 is the pivotal phase 3 trial that established once-weekly semaglutide 2.4 mg as a weight-management therapy. It randomized 1,961 adults with obesity (BMI >= 30) or overweight (BMI >= 27 with at least one weight-related coexisting condition) who did not have diabetes to semaglutide 2.4 mg or placebo, each as an adjunct to lifestyle intervention, for 68 weeks.[1,2]
The headline result: mean body weight changed by about -14.9% with semaglutide versus about -2.4% with placebo at week 68, a treatment difference of roughly 12.4 percentage points.[1] This scale of medical weight loss, sustained over more than a year, was a step change from earlier pharmacotherapy.
In adults with obesity without diabetes, semaglutide 2.4 mg gave about 14.9% mean weight loss over 68 weeks, with most participants crossing clinically meaningful thresholds.[1] The STEP program supported the FDA approval of Wegovy on June 4, 2021.[3]
Who was studied
The population matters for interpretation: these were adults without type 2 diabetes. Weight loss with GLP-1 therapy tends to be somewhat smaller in people with diabetes, so STEP 1 figures should not be read directly across to a diabetic population.[1,2]
What the trial showed
Beyond the mean, STEP 1 reported how many participants reached categorical weight-loss thresholds, which is often the more clinically useful framing.[1]
Proportion of participants reaching each weight-loss threshold at week 68, semaglutide 2.4 mg versus placebo.
| Endpoint | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Mean body-weight change | About -14.9% | About -2.4% |
| Lost >= 5% of body weight | 86.4% | 31.5% |
| Lost >= 10% of body weight | 69.1% | 12.0% |
| Lost >= 15% of body weight | 50.5% | 4.9% |
Figures are from the primary STEP 1 publication.[1]
Dosing and tolerability
Semaglutide was titrated to the 2.4 mg target dose over a 16-week escalation, a schedule designed to limit gastrointestinal effects.[1] Nausea, diarrhea, vomiting, and constipation were the most common adverse events and were mostly transient and mild to moderate. Gastrointestinal events drove more discontinuations on semaglutide than on placebo (about 4.5% versus 0.8%).[1] Slow escalation and symptom management are central to real-world tolerability.
Why it mattered
STEP 1 was the largest of the four phase 3a trials in the STEP program that supported regulatory approval. On June 4, 2021, the FDA approved semaglutide 2.4 mg (Wegovy) for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, as an adjunct to a reduced-calorie diet and increased physical activity.[3]
Roughly 15% mean weight loss, sustained over 68 weeks, in people without diabetes - that is the number STEP 1 is remembered for, and the basis for the weight-management approval.- Section synthesis
The library is curated. The product is asked.
A trial like STEP 1 raises the next questions: who is a candidate, how fast to escalate the dose, and how to manage GI side effects. Ask, and read the trial.
This explainer is verified against the cited primary sources. Trial figures and approval details should be confirmed against the primary publication and current labeling before clinical use.
Medical AI returns evidence-grounded answers backed by real citations. It is a reference tool, and these terms describe how it should and should not be used.
01 Educational purpose
Medical AI is an information and reference tool intended for educational use only. The answers it returns are not medical advice, diagnosis, or treatment. Always consult a qualified doctor or healthcare professional with any question concerning a medical condition.
02 Professional use
Medical AI is designed for use by practicing clinicians. It is not intended for direct patient use and is not a substitute for professional clinical judgment. Apply your own training and current guidelines to every decision an answer informs.
03 Privacy and data
We do not collect, store, or process personally identifiable patient information (PHI or PII). Do not enter names, dates of birth, medical record numbers, or any other patient identifiers into the composer.
04 Information currency
Medical knowledge evolves rapidly. Citations carry their publication date, so consult the primary source and the most recent clinical guideline before acting on anything material.